HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.6%

Neg 0% Neu 89.6% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $25 price target.